Pharmaceutical Significant research news last week included a setback for Pliant Therapeutics, when it paused a Phase IIb trial of its bexotegrast in idiopathic pulmonary fibrosis (IPP). Also, US biotech AnaptysBio released positive new Phase II data on its rosnilimab in rheumatoid arthritis that attracted attention. On the regulatory front, US drug developer BridgeBio Pharma last week gained European Commission (EC) approval for its Beyonttra (acoramidis) for cardiomyopathy (ARRR-CM). The EC also granted approval for Kostaive, an mRNA COVID-19 vaccine developed by US firm Arcturus Therapeutics and licensed to CSL Limited for European marketing. 16 February 2025